Amendments to the claims:

1-48. (cancelled)

49. (previously presented) A purified monoclonal antibody produced by the cell line named KRIX 1 deposited with the Belgian Coordinated Collections of Micro-organisms, under accession number LMBP 5089CB.

50. (currently amended) An antigen-binding fragment Fab, Fab', ~~or~~ $F(ab')_2$ or scFV, of a monoclonal antibody according to claim 49, said fragment binding the C1 domain of fVIII and having the capacity to partially inhibit fVIII activity.

51. (previously presented) A cell line named KRIX 1 deposited with the Belgian Coordinated Collections of Micro-organisms, under accession number LMBP 5089CB.

52. (currently amended) A purified monoclonal antibody or fragment thereof binding the C1 domain of fVIII comprising a variable heavy sequence being at least 80% identical to the amino acid sequence of the complementarity determining regions depicted in figure 8, and/~~or~~ a variable light chain sequence being at least 80% identical to the amino acid sequence of the complementarity determining regions depicted in figure 9, said monoclonal antibody having the capacity of partially inactivating factor VIII activity when said monoclonal antibody is in a ~~physiological~~ molar excess.

53. (currently amended) A pharmaceutical composition for ~~the prevention or treatment of disorders of hemostasis and resulting pathologic conditions in mammals,~~ preventing or treating a thrombotic pathological condition in a mammal, comprising as an active ingredient the monoclonal antibody produced by the cell line named KRIX 1 deposited with the Belgian Coordinated Collections of Micro-organisms, under accession number LMBP 5089CB, or an antigen-binding fragment Fab, Fab', ~~or~~ $F(ab')_2$ or scFV thereof, said fragment binding the C1 domain of fVIII and having the capacity to partially inhibit fVIII activity, in admixture with a pharmaceutically acceptable carrier.

54. (previously presented) A pharmaceutical composition according to claim 53, further comprising a therapeutically effective amount of a thrombolytic agent.

55. (previously presented) A pharmaceutical composition ~~for the prevention or treatment of disorders of hemostasis and resulting pathologic conditions in mammals~~ preventing or treating a thrombotic pathological condition in a mammal, comprising the monoclonal antibody or fragment of claim 52.

56. (currently amended) A method of obtaining a monoclonal antibody from a non-human mammal comprising the steps of:

a) selecting a non-human mammal having a modified ~~and partially functional~~ FVIII protein, the modification being with respect to a wild type FVIII protein and lying in the C1 domain of the FVIII protein,

b) administering the wild type FVIII protein to the non-human mammal in order to elicit an immune response, and

c) selecting B-lymphocytes from the non-human mammal which produce antibodies which only partially inactivate the wild type FVIII protein.

57. (currently amended) A method of obtaining a monoclonal antibody from B-lymphocytes obtained from the blood of a human having a modified and partially functional FVIII protein, the modification being with respect to wild type protein and lying in the C1 domain of the protein, and to whom the FVIII wild type protein was administered, said method comprising the steps of a) obtaining peripheral blood from a human, b) selecting, from the blood of said human ~~being~~, B-lymphocytes which produce antibodies which only partially inactivate the wild type FVIII protein, c) cloning said B-lymphocytes and d) purifying said monoclonal antibodies produced by said cloned B-lymphocytes.